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ABSTRACT There is an urgent need to develop novel antifungals to tackle the
threat fungal pathogens pose to human health. Here, we have performed a compre-
hensive characterization and validation of the promising target methionine synthase
(MetH). We show that in Aspergillus fumigatus the absence of this enzymatic activity
triggers a metabolic imbalance that causes a reduction in intracellular ATP, which
prevents fungal growth even in the presence of methionine. Interestingly, growth
can be recovered in the presence of certain metabolites, which shows that metH is a
conditionally essential gene and consequently should be targeted in established in-
fections for a more comprehensive validation. Accordingly, we have validated the
use of the tetOFF genetic model in fungal research and improved its performance in
vivo to achieve initial validation of targets in models of established infection. We
show that repression of metH in growing hyphae halts growth in vitro, which trans-
lates into a beneficial effect when targeting established infections using this model
in vivo. Finally, a structure-based virtual screening of methionine synthases re-
veals key differences between the human and fungal structures and unravels fea-
tures in the fungal enzyme that can guide the design of novel specific inhibitors.
Therefore, methionine synthase is a valuable target for the development of new
antifungals.
IMPORTANCE Fungal pathogens are responsible for millions of life-threatening infec-
tions on an annual basis worldwide. The current repertoire of antifungal drugs is very
limited and, worryingly, resistance has emerged and already become a serious threat to
our capacity to treat fungal diseases. The first step to develop new drugs is often to
identify molecular targets in the pathogen whose inhibition during infection can prevent
its growth. However, the current models are not suitable to validate targets in estab-
lished infections. Here, we have characterized the promising antifungal target methio-
nine synthase in great detail, using the prominent fungal pathogen Aspergillus fumigatus
as a model. We have uncovered the underlying reason for its essentiality and confirmed
its druggability. Furthermore, we have optimized the use of a genetic system to show a
beneficial effect of targeting methionine synthase in established infections. Therefore,
we believe that antifungal drugs to target methionine synthase should be pursued and
additionally, we provide a model that permits gaining information about the validity of
antifungal targets in established infections.
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Fungal pathogens represent an increasing risk to human health (1), with over onebillion people worldwide affected by mycoses annually. Many of these mycoses are
superficial infections of the skin, nails or mucosal membranes and although trouble-
some are usually not life-threatening. However, some fungi cause devastating chronic
and invasive fungal infections, which result in an estimated 1.6 million deaths per year
(2). Incidences of invasive infections caused by Aspergillus, Candida, Cryptococcus, and
Pneumocystis species are increasing (3), a cause for serious concern as these genera are
responsible for 90% of deaths caused by mycoses (4). Despite the availability of
antifungal drugs, the mortality rates for invasive aspergillosis, invasive candidiasis,
cryptococcal meningitis, and Pneumocystis jirovecii pneumonia are intolerably high,
reaching more than 80, 40, 50, and 30%, respectively (2, 5). There are currently only four
classes of antifungals in clinical use to treat invasive infections (azoles, echinocandins,
polyenes, and flucytosine), all suffering from pharmacological drawbacks, including
toxicity, drug-drug interactions, and poor bioavailability (6, 7). With the sole exemption
of flucytosine, which is only used in combinatory therapy with amphotericin B for
cryptococcal meningitis and Candida endocarditis (7), the current antifungals target
critical components of the fungal cell membrane or cell wall (8), which represents a very
limited druggable space. The rise of antifungal resistance presents an additional
challenge as mortality rates in patients with resistant isolates can reach 100%, making
the development of new antifungal drugs increasingly critical for human health (1, 9).
Targeting fungal primary metabolism is broadly considered a valid strategy for the
development of novel antifungals, as it is crucial for pathogen virulence and survival
(10, 11). A primary example of a success of this strategy is olorofim (F901318), a novel
class of antifungal that targets the pyrimidine biosynthesis pathway (12), which is
currently in clinical trials.
Methionine synthases catalyze the transfer of a methyl group from N5-methyl-
5,6,7,8-tetrahydrofolate (CH3-THF) to L-homocysteine (Hcy), as shown in Fig. 1A. Two
unrelated protein families catalyze this reaction: cobalamin-dependent methionine
synthases (EC 2.1.1.13) and cobalamin independent methionine synthases (EC 2.1.1.14).
Members of both families must catalyze the transfer of a low active methyl group from
the tertiary amine, CH3-THF, to a relatively weak nucleophile, Hcy sulfur. Cobalamin-
dependent enzymes facilitate this transfer by using cobalamin as an intermediate
methyl carrier (13). In contrast, cobalamin-independent enzymes directly transfer the
methyl group from CH3-THF to Hcy (14). Logically, proteins of each family differ
significantly both at the amino acid sequence (15) and three-dimensional (3D) structure
level (16). Interestingly, fungi encode cobalamin-independent methionine synthases,
whereas humans have only the cobalamin-dependent enzyme, opening the possibility
to target fungal enzymes for antifungal therapy.
We have previously shown that the methionine synthase-encoding gene (metH,
AFUA_4G07360) is essential for A. fumigatus viability and virulence, which led us to
propose it as a promising target for antifungal drug development (17). In support of
this, a systematic metabolic network analysis by Kaltdorf et al. identified methionine
synthase as a promising antifungal drug target worthy of investigation (11). Methionine
synthase has also been described as essential for Candida albicans viability (18, 19) and
necessary for Cryptococcus neoformans pathogenicity (20), which suggests that a drug
developed against this enzyme may have a broad spectrum of action. Moreover, fungal
methionine synthases are cobalamin independent, differing significantly from the
cobalamin-dependent human protein at the amino acid sequence level: only 11.2%
identity, 20.4% similarity, and 60.2% gaps when the A. fumigatus and human proteins
were aligned using L-Align from EMBL (21, 22). Therefore, it should be possible to
develop drugs with low toxicity potential.
Target validation is critical and has been suggested as the most important step in
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translating a new potential target into a viable drug target because of its role in
achieving efficacy in patients (23). Indeed, a retrospective analysis from AstraZeneca’s
drug pipeline showed that projects that had performed a more thorough target
validation were less likely to fail: 73% of the projects were active or successful in phase
II compared to only 43% of projects without such extra target validation (24). Therefore,
in the present study we aimed to further substantiate methionine synthase’s potential
as an antifungal drug target, before advancing the drug discovery process. In particular,
we were interested in (i) unraveling the mechanistic basis of methionine synthase
essentiality in A. fumigatus, which is needed to fully explore the potential of this
enzyme as a drug target and to be able to anticipate drug resistance mechanisms, and
(ii) developing in vivo models of infection to mimic treatment against the target in an
established infection and using them to validate methionine synthase as an antifungal
drug target.
RESULTS AND DISCUSSION
Methionine synthase enzymatic activity is essential for Aspergillus fumigatus
viability. We had previously demonstrated that the methionine synthase encoding
FIG 1 Methionine synthase (MetH) enzymatic activity is essential for A. fumigatus viability. (A) Schematic representation of the trans-sulfuration pathway and
its intersection with the one carbon metabolic route. (B) Both strains, a metF mutant (which blocks the one carbon metabolism route) and a metG cysD
mutant (which blocks the trans-sulfuration pathway) could grow in the presence of methionine. In contrast, the metH_tetOFF strain (H_OFF) could not grow
in restrictive conditions (Dox) even if methionine was supplemented. The phenotypic analysis was repeated in three independent experiments. Representative
plates are shown. (C) A second copy of the metH gene under the control of its own promoter was introduced in the innocuous Ku70 locus of the H_OFF
background strain. Two point-mutated versions of the gene were introduced, one that causes a D¡A substitution in amino acid 616 and another one that
causes a Y¡A substitution in amino acid 662. In nonrestrictive conditions all strains were able to grow as the parental H_OFF strain. In the presence of Dox
and absence of Met, the Y662A protein was able to trigger significant growth, suggesting that its enzymatic activity is impaired but not blocked. In the presence
of Met, the Y662A strain grew as well under restrictive as under nonrestrictive conditions, suggesting that partial enzymatic activity is sufficient to cover the
essential function of MetH. In restrictive conditions and absence of methionine, the D616A strain was not able to grow, indicating that enzymatic activity is
blocked in this mutated protein. The D616A was also not able to grow in the presence of Dox and Met, indicating that enzymatic activity is required for the
essential function of MetH. The phenotypic analysis was repeated in three independent experiments. Representative plates are shown.
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gene is essential for A. fumigatus viability and virulence (17); however, the underlying
reason for this essentiality was still unclear. To address this question, we constructed
strains that express the metH gene under the control of a tetOFF system recently
adapted for Aspergillus (25) in two different A. fumigatus wild-type backgrounds, ATCC
46645 and A1160. The advantage of the tetOFF system over other regulatable systems
is that doxycycline (Dox) can be added to downregulate gene expression in growing
hyphae (see Fig. S1A in the supplemental material), and thus this system permits
investigation of the consequences of the repression of an essential gene in growing
mycelia. The constructed metH_tetOFF strains (H_OFF) grew as the wild type in the
absence of Dox, but as little as 0.5 g/ml was sufficient to completely prevent colony
development on an agar plate even in the presence of methionine (see Fig. S1B). This
corroborates our previous result that methionine synthase is essential for A. fumigatus
viability, meaning that its absence does not simply cause methionine auxotrophy (17).
Methionine synthase forms an intersection between the trans-sulfuration pathway
and the one carbon metabolic route (Fig. 1A), as the enzyme utilizes 5-methyl-
tetrahydrofolate as cosubstrate. Therefore, metH might be essential due to the disrup-
tion of the trans-sulfuration pathway or of the one carbon metabolic route upon its
absence. Alternatively, it could be that the presence of the enzyme itself is essential,
either because its enzymatic activity is required or because it is fulfilling an unrelated
additional role, such as being part of a multiprotein complex. To differentiate between
these possibilities, we constructed a double metG cysD mutant, blocked in the
previous step of the trans-sulfuration pathway, and a metF deletant, which blocks the
previous step of the one-carbon metabolic route (Fig. 1A). As we had previously
observed (26), to fully rescue metF’s growth the media had to be supplemented with
methionine and other amino acids (see Fig. S1C), as the folate cycle is necessary for the
interconversion of serine and glycine and plays a role in histidine and aromatic amino
acid metabolism (27, 28). Consequently, we added a mix of all amino acids except
cysteine and methionine (aac) to the S-free medium for this experiment. Phenotypic
tests (Fig. 1B) confirmed that the metG cysD and metF mutants were viable and
could grow in the presence of methionine. In contrast, the H_OFF conditional strain
could not grow under restrictive conditions even in the presence of the amino acid mix
and methionine (Fig. 1B). Therefore, the MetH protein itself, and not the integrity of the
trans-sulfuration and one-carbon pathways, is essential for A. fumigatus viability. Inter-
estingly, the true methionine auxotroph metG cysD (see Fig. S1C) was avirulent in a
leukopenic model of pulmonary aspergillosis (see Fig. S1D), suggesting that the
amount of readily available methionine in the lung is very limited, not sufficient to
rescue its auxotrophy. Indeed, the level of methionine in human serum was calculated
to be as low as 20 M (29, 30), which was described as insufficient to support the
growth of various auxotrophic bacterial pathogens (31), and we have also observed
that this is not enough to rescue growth of the A. fumigatus metG cysD auxotroph
(Fig. S1C).
The essentiality of the MetH protein could be directly linked to its enzymatic activity
or, alternatively, the protein could be performing an additional independent function.
To discern between these two possibilities, we constructed two strains that express
single-point mutated versions of MetH from the neutral Ku70 locus (32) of the H_OFF
background strain, under the control of its native promoter (Fig. 1C). These point
mutations, metHg2042AC (D616A) and metHg2179TAGC (Y662A), were previously de-
scribed to prevent conformational rearrangements required for activity of the C.
albicans methionine synthase (33). In the absence of Dox, these strains grew normally,
as they expressed both the wild-type MetH, from the tetOFF promoter, and the
mutated version of the protein (Fig. 1C). In the presence of Dox, when the wild-type
metH gene was downregulated, the Y662A strain grew on sulfate worse than in
nonrestrictive conditions, but still to a significant extent, suggesting that this point
mutation did not completely abrogate enzymatic activity (Fig. 1C). Interestingly, Y662
grew normally on methionine, showing that methionine can compensate for a partial
reduction of MetH activity (Fig. 1C). The D616A mutated protein was confirmed to be
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stable as a green fluorescent protein (GFP)-tagged version of this protein could be
visualized under nonrestrictive (–Dox) conditions (see Fig. S1E and strain discussed in
more detail later in this article). Interestingly, the D616A strain (two isolates were
tested) was not able to grow on sulfate (Fig. 1C), demonstrating that enzymatic activity
was fully blocked. Nor could it grow on methionine (Fig. 1C), indicating that enzymatic
activity is required for viability even in the presence of the full protein. All of these
phenotypes support the conclusion that methionine synthase enzymatic activity is
required for viability.
Absence of methionine synthase enzymatic activity results in a shortage of
crucial metabolites but does not cause toxic accumulation of homocysteine. The
absence of methionine synthase enzymatic activity has two direct consequences, which
could cause deleterious effects and therefore explain its essentiality even under me-
thionine supplementation (Fig. 1A). It could cause an accumulation of the potentially
toxic substrate homocysteine and/or a shortage of the coproduct tetrahydrofolate
(THF). THF is directly converted to 5,10-methylene-THF, which is required for the
synthesis of purines and thymidylate and thus for DNA synthesis; additionally, since
purine biosynthesis requires Gln, Gly, and Asp, and as THF de novo synthesis requires
chorismate (precursor of aromatic amino acids), a shortage of THF might cause a
depletion of amino acids (Fig. 1A). To investigate whether the depletion of any of these
metabolites underlies MetH essentiality, we supplemented the media with a number of
precursors and potentially depleted metabolites (Fig. 2A). Added as the sole supple-
ment, only adenine was able to trigger growth, but to a minimal degree. Further
addition of a mixture of all amino acids noticeably improved growth. Supplementation
with adenine and guanine (purine bases) did also reconstitute noticeable growth,
which was not enhanced with further addition of amino acids. Folic acid was also
capable of reconstituting growth, but only when amino acids were added as the sole
N source (Fig. S2A). However, no combination of compounds was able to reconstitute
growth to the wild-type level. This suggests that a shortage of relevant metabolites
FIG 2 Shortage of important downstream metabolites, but not the toxic accumulation of homocysteine,
partially accounts for MetH essentiality. (A) Minimal medium containing 5 mM Met and 5 g/ml Dox was
supplemented with a variety of metabolites (potentially relevant for downstream processes [see Fig. 1A])
in single and multiple addition. Growth assays showed that purines (adenine A and guanine G, 3 mM) could
slightly reconstitute growth of the H_OFF strain. Additional supplementation with amino acids improved
growth, but not to the wild-type levels. Folic acid (5 mM) could also reconstitute growth, but only when
amino acids were the only N source. (B) Overexpression of genes that could detoxify a potential accumu-
lation of homocysteine did not reconstitute growth in the absence of MetH activity. Further addition of
adenine did not improve growth. The phenotypic analyses were repeated in three independent experi-
ments. Representative plates are shown.
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derived from THF, predominantly adenine, partially accounts for methionine synthase
essentiality even under methionine supplementation but cannot explain it completely.
In other fungi, such as Pichia pastoris (34) or Schizosaccharomyces pombe (35), supple-
mentation with methionine and adenine was found to restore growth of a metH mutant
to wild-type levels, indicating that these are combined auxotrophs. In A. fumigatus it
seems to be more complex because supplementation with methionine, adenine, and
other amino acids could still not fully restore growth, suggesting that more factors are
implicated.
To investigate whether homocysteine could be accumulating to toxic levels in the
absence of MetH activity, we overexpressed several genes that should alleviate its
accumulation. To do this, we designed and constructed the plasmid pJA49, which
allows direct integration of any open reading frame (ORF) to episomally overexpress
genes in A. fumigatus. Plasmid pJA49 carries the A. nidulans AMA1 autologous repli-
cating sequence (36, 37) and the hygromycin B resistance gene (hygrB) as a selection
marker. A unique StuI restriction site allows introduction of any PCR amplified ORF in
frame under the control of the A. fumigatus strong promoter hspA (38) and the A.
nidulans trpC terminator (see Fig. S1F). Using this plasmid, we produced a strain in the
H_OFF background that episomally overexpresses mecA, encoding cystathionine--
synthase, which converts homocysteine to cystathionine (Fig. 1A). Homocysteine
exerts toxic effects through its conversion to S-adenosylhomocysteine, which causes
DNA hypomethylation (39, 40), or to homocysteine thiolactone, which causes N-homo-
cysteinylation at the -amino group of protein lysine residues (41, 42). Consequently,
we also constructed strains that episomally overexpress genes that could detoxify those
products: the S-adenosyl-homocysteinase lyase encoding gene sahL (AFUA_1G10130)
or the A. nidulans homocysteine thiolactone hydrolase encoding gene blhA (AN6399)
(A. fumigatus genome does not encode any orthologue) (see Fig. S1G). However,
despite a strong overexpression of the genes (see Fig. S1H and I), none of them could
rescue growth of the H_OFF strain in restrictive conditions (Fig. 2B). Therefore, our
overexpression experiments suggest that homocysteine accumulation is not responsi-
ble for metH essentiality, but additional experiments such as quantification of homo-
cysteine levels, which are currently challenging, would be required to further support
this hypothesis. The addition of adenine to the medium did not improve growth of the
overexpression strains further than that of the H_OFF background (Fig. 2B), indicating
that methionine synthase essentiality seemingly is not a combined effect of homocys-
teine accumulation and depletion of THF-derived metabolites. Toxic accumulation of
homocysteine was speculated to be the underlying reason of methionine synthase
essentiality in both Candida albicans and Cryptococcus neoformans (19, 20), but our
results suggest that this is not the case in A. fumigatus. Therefore, we propose that the
previous assumption should be revisited in other fungal pathogens.
Methionine synthase repression triggers a metabolic imbalance that causes a
decrease in cell energetics. Aiming to identify any adverse metabolic shift in the
absence of MetH and/or accumulation of toxic compounds that could explain its
necessity for proper growth, we performed a metabolomics analysis, via gas
chromatography-mass spectrometry (GC-MS), comparing the metabolites present in
wild-type and H_OFF strains before and 6 h after Dox addition. Before Dox addition,
both strains clustered closely together in a principal component analysis (PCA) scores
plot (see Fig. S3A), showing that their metabolic profiles are highly similar. However, 6
h after Dox addition the strains clusters became clearly separated, denoting differential
metabolite content. Analysis of the differentially accumulated metabolites (a full list is
shown in Table S1 in the supplemental material) using the online platforms MBRole (43)
and Metaboanalyst (44, 45) did not reveal any obvious metabolic switch, probably due
to the rather small number of metabolites that could be identified by cross-referencing
with the Golm library (http://gmd.mpimp-golm.mpg.de/). Manual inspection of the
metabolites pointed out interesting aspects. First, the methionine levels were not
significantly different, which demonstrates that methionine supplementation in the
growth medium triggers correct intracellular levels in the H_OFF strain; this undoubt-
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edly rules out that a shortage of methionine could be the cause of the essentiality of
methionine synthase. Second, we detected a significantly smaller amount of adenosine
in the H_OFF strain compared to the wild-type after Dox addition (Fig. 3A), which is in
agreement with our previous result that supplementation of adenine can partially
reconstitute growth in the absence of MetH. We did not find accumulation of com-
pounds with a clear toxic potential upon metH repression. Nevertheless, we detected a
smaller amount of several amino acids (Phe, Ser, Glu, Pro, Ile, Thr, Ala, and Asp; see
FIG 3 Lack of methionine synthase activity causes a decrease in cell energetics. (A) Normalized concentrations of metabolites in fungal mycelia (n  8).
Adenosine levels were decreased in H_OFFDox compared to wild type  Dox (wtDox), which agrees with its capacity to partially reconstitute growth.
Several metabolites of the glycolysis and TCA pathways were reduced in H_OFFDox compared to wtDox, suggesting low energetic levels. (B) The levels of
ATP significantly decreased in the H_OFF strain upon Dox addition, while they did not vary significantly in the wild-type strain. Each point represents a biological
replicate, which was assayed with three technical replicates. Data were analyzed by using a one-sample t test to a hypothetical value of 100 (i.e., no change
in ratio of ATP). Graph displays the mean and standard deviations (SD). (C) Pyruvate as the sole carbon source could reconstitute growth of the H_OFF strain
in restrictive conditions to wild-type levels. For both strains, growth was limited and slightly improved in the presence of amino acids (aac). ATP could fully
reconstitute growth of H_OFF when amino acids were the sole N source. The phenotypic analyses were repeated in three independent experiments.
Representative plates are shown. (D) RT-PCR calculation of the fold change in genetic expression of metF and G6PD with respect to their expression in wild type
without Dox. Each point represents a biological replicate which was analyzed with three technical replicates. Data were analyzed by using a one-sample t test
to a hypothetical value of 1 (i.e., no change in expression). The graphs display the means and SD. (E) Schematic representation of the metabolic imbalance
started with MetH repression (1). Lack of the enzymatic activity caused a shortage of 5,10-methylene-THF and consequently of purine rings (2). This was sensed
as a shortage of nucleotides that the cell attempted to compensate through an unknown mechanism, seemingly TOR and PKA independent (3), that activated
glucose flow through the pentose phosphate pathway (PPP) (4). That caused a reduction of glycolysis and TCA cycles, which in turn decreased ATP levels (5).
ATP usage for S-adenosylmethionine (SAM) synthesis was maintained, which caused a drop in cell energy that resulted in growth arrest (6). Genes/pathways/
compounds expected to be reduced are highlighted in green and those increased in magenta.
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Fig. S3B), which may suggest that the cells have a reduced growth rate upon metH
repression. Interestingly, we noticed a significantly lower accumulation of some me-
tabolites of the glycolysis pathway and tricarboxylic acid (TCA) cycle (Fig. 3A) and some
other mono- and polysaccharides (see Fig. S3B). These variations could reflect a low
energetic status of the cells upon metH repression. Indeed, we found that the level of
ATP significantly decreased in the H_OFF strain, but not in the wild type, upon Dox
addition (Fig. 3B). Therefore, we evaluated whether supplementation of the medium
with substrates that have the potential to increase cell energetics can rescue H_OFF
growth in restrictive conditions. We found that when pyruvate, which can directly be
converted to acetyl coenzyme A to enter the TCA cycle, was added as the sole carbon
source H_OFF growth was reconstituted in restrictive conditions to the same level as
the wild type (Fig. 3C). Growth was limited for both strains, since pyruvate does not
appear to be a good carbon source (46). However, the presence of glucose in the
medium precluded the reconstitution of growth of H_OFF (see Fig. S2A), probably
because glucose prevents pyruvate uptake, as has been been reported in S. cerevisiae
(47). We next tested the capacity of ATP to be used as an alternative energy source and
to reconstitute growth. To diversify the presence of permeases in the cell membrane,
and thus maximize the chance of ATP uptake, we assayed two different N sources:
ammonium (NH4, preferred source) and amino acids (see Fig. S2A). Indeed, when
amino acids were the only N source, supplementation of the medium with ATP
reconstituted H_OFF growth in restrictive conditions to wild-type levels (Fig. 3C; see
also Fig. S2A and B in the supplemental material). This agrees with the recent obser-
vation that eukaryotic cells can uptake ATP and exploit it as an energy source (48).
Interestingly, AMP supplementation also reconstituted H_OFF growth in restrictive
conditions to wild-type levels (Fig. S2B). We speculate that this might be due to the
known functions of AMP to activate AMP-activated protein kinase (AMPK; an energy
sensor that restores cellular energy balance by switching on catabolic, ATP-generating
pathways while switching off anabolic, ATP-consuming pathways [49]) and to stimulate
glycolysis (via activation of phosphofructokinase [50, 51]). In conclusion, a decrease in
cell energetics developed in the absence of methionine synthase seems to explain
MetH essentiality for growth.
The fact that growth in the absence of methionine synthase can be reconstituted
when there are sufficient levels of methionine and ATP implies that metH is a condi-
tionally essential gene, meaning that it is only essential in the absence of the specific
conditions that overcome the disturbances derived from its deficiency. We believe that
a significant number of genes previously described as essential in fungi would in fact
be conditionally essential; however, the right conditions to reconstitute growth have
not been identified in many cases. This highlights a paramount consideration for the
proper identification and validation of drug targets: the deficiencies introduced by
targeting a conditionally essential gene must not be overcome during infection. This
important concept has already been discussed by others (52–55), and we believe
addressing it should become a priority for proper validation of antimicrobial targets. In
the case of methionine synthase, it is unlikely that the fungus could acquire sufficient
levels of ATP (combined with methionine and not using a preferred N source) in the
lung tissue to overcome the growth defect resulting from targeting MetH. The con-
centration of free extracellular ATP in human plasma has been calculated to be in the
submicromolar range (28 to 64 nM) (56). In the lungs, extracellular ATP concentrations
must be strictly balanced and increased levels are implicated in the pathophysiology of
inflammatory diseases (57); nevertheless, even in such cases ATP levels have been
calculated in the low micromolar range (58, 59). Despite this low concentration and
consequently unlikely compensation, we believe that MetH needs to be validated in a
suitable model to confirm that its deficiency cannot be not overcome in established
infections.
We then questioned how the lack of methionine synthase’s enzymatic activity could
cause a drop in cell energy. We hypothesized that blockage of methionine synthase
activity likely causes a forced conversion of 5,10-methylene-THF to 5-methyl-THF by the
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action of MetF (Fig. 1A). In support of this, we observed that expression of metF was
increased in the H_OFF strain (Fig. 3D). This likely causes a shortage of 5,10-methylene-
THF, since the conversion is not reversible and THF cannot be recycled by the action of
methionine synthase (Fig. 1A). Indeed, supplementation of folic acid (only when amino
acids are the sole N source; see Fig. S2A in the supplemental material) and of purine
bases could partially restore growth (Fig. 2A), since they compensate for the deficit in
purine ring biosynthesis when there is a shortage of 5,10-methylene-THF. However, this
still does not explain why there is a drop in ATP. We hypothesized that the block of
purine biosynthesis might be sensed as a shortage of nucleotides. This could then
cause a shift in glucose metabolism from glycolysis and the TCA cycle (which produce
energy) to the pentose phosphate pathway (PPP), which is required to produce
ribose-5-phosphate, an integral part of nucleotides. In support of our hypothesis, a
recent publication found that a feedback-insensitive, constitutively active methylene-
tetrahydrofolate reductase (MetF) enzyme causes depletion of nucleotides and re-
duction of ATP in S. cerevisiae (113). It has also been described that activation of
anabolism in S. cerevisiae implies increased nucleotide biosynthesis and consequently
metabolic flow through the PPP (60). To evaluate our hypothesis, we investigated the
transcription level of the glucose-6-phosphate dehydrogenase (G6PD) encoding gene
(AFUA_3G08470), which catalyzes the first committed step of the PPP. In agreement
with our hypothesis, the expression of G6PD encoding gene increases in the H_OFF
strain upon addition of Dox (Fig. 3D), likely reflecting an increased flow through the
PPP. We then wondered how cells may be activating the PPP. The target of rapamycin
(TOR) TORC1 effector, which is widely known to activate anabolism and growth (61–63),
has been described to activate the PPP in mammalian cells (64, 65) and has been
functionally connected with energy production and nucleotide metabolism in A. fu-
migatus (66). In addition, the cAMP/PKA (cyclic AMP/protein kinase A) pathway is
known to be paramount for sensing of nutrients and the correspondent adaptation of
gene expression and metabolism (67) and was found to be implicated in the regulation
of nucleotide biosynthesis in A. fumigatus (68). Consequently, we explored whether a
partial block of TOR with low concentrations of rapamycin or of PKA with H-89 could
prevent the imbalanced activation of the PPP in the absence of MetH activity. However,
neither of the inhibitors could reconstitute growth of the H_OFF strain in restrictive
conditions (see Fig. S3C). This means that neither the TOR nor the PKA pathways seem
to be involved in the deleterious metabolic shift that seemingly activates PPP and
decreases flux through glycolysis. Therefore, more experiments are required to eluci-
date the mechanism underlying the metabolic imbalance developed upon metH down-
regulation.
In summary, we propose that absence of methionine synthase activity causes a
strong defect in purine biosynthesis that the cell tries to compensate for by shifting
carbon metabolism to the PPP; this metabolic imbalance causes a drop of ATP levels,
which collapses cell energetics and results in halted growth (Fig. 3E).
Interestingly, we also detected that metF expression is higher in the H_OFF strain
compared to the wild-type, even in the absence of Dox (Fig. 3D). This could be
explained as an effort to compensate a higher demand of 5-methyl-THF by the slightly
increased amount of methionine synthase in this strain (Fig. S1A). This effect could
cause a mild defect in purine biosynthesis in the H_OFF strain, and indeed adenosine
content was lower in the H_OFF–Dox condition compared with the wild-type–Dox
sample in the metabolome analysis (Fig. 3A). Furthermore, this also explains why we
detected a small but significant increase of G6PD expression in the H_OFF–Dox
condition (Fig. 3D). Therefore, it seems that upregulating methionine synthase has the
potential to cause the same metabolic imbalance as downregulating it. However, the
effect of overexpression (notice that it is only 1.5-fold in our strain; see Fig. S1A) is
minor and does not have obvious consequences for growth, since THF can be recycled,
and thus the shortage of 5,10-methylene-THF is not severe. In any case, two important
points can be highlighted from this small imbalance. First, methionine synthase activity
is very important and must be finely tuned to maintain a proper metabolic homeosta-
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sis. Second, changing the expression level of genes with constitutive and/or regulatable
promoters can have unexpected and hidden consequences that often go unnoticed.
Supplementation with S-adenosylmethionine reconstitutes ATP levels and
growth. We have shown that the absence of MetH activity causes a reduction in ATP
levels. S-Adenosylmethionine (SAM) is produced from methionine and ATP by the
action of S-adenosylmethionine synthetase SasA (Fig. 1A), an essential enzyme in A.
nidulans (69). Hence, we reasoned that the absence of MetH activity might cause a
decrease in SAM levels. To test that hypothesis, we first attempted to rescue growth of
the H_OFF strain in a medium supplemented with methionine and SAM. We tested
various N sources to diversify the presence of permeases in the cell membrane, aiming
to maximize the chances of SAM uptake (see Fig. S2A). Indeed, the addition of SAM
reconstituted growth of the H_OFF strain in restrictive conditions in the presence of
methionine when amino acids were the only N-source (Fig. 4A; see also Fig. S2 in the
supplemental material). We then measured the intracellular concentration of SAM in
growing mycelia upon addition of Dox using tandem mass spectrometry (MS/MS).
Surprisingly, we observed that addition of Dox to the H_OFF strain did not cause a
significant reduction in SAM levels (Fig. 4B). Consequently, we wondered how the
addition of SAM may reconstitute H_OFF growth if its levels are not reduced upon metH
repression. We speculated that as SAM is a crucial molecule it continues to be produced
even if the levels of ATP are reduced, draining it from other cellular processes and thus
triggering energy deprivation. In support of this hypothesis, we observed that supple-
menting SAM to the medium increased the levels of ATP in growing hyphae (Fig. 4C).
Similarly, futile cycles of SAM formation and recycling were shown to cause ATP
depletion upon deregulation of methylenetetrahydrofolate reductase (MetF) activity
in S. cerevisiae (113). It is also possible that added SAM allosterically inhibits MetF
activity (113), preventing development of the deleterious metabolic imbalance, but this
is unlikely as the levels of SAM did not decrease upon Dox addition in the H_OFF strain.
Since SAM supplementation can reconstitute H_OFF growth, it constitutes another
condition that overcomes the conditional essentiality of metH, highlighting again the
need to validate MetH in a model of established infection. The concentration of SAM in
human serum is extremely low, in the range of 100 to 150 nM (30), and consequently
FIG 4 External SAM reconstitutes ATP levels and growth. (A) The addition of SAM to the medium reconstituted
growth of the H_OFF strain in restrictive conditions. The phenotypic analysis was repeated in two independent
experiments. Representative plates are shown. (B) The levels of SAM did not significantly decrease upon Dox
administration (5 g/ml) in wild-type or H_OFF strains. Graphs depict the means and SD of three biological and two
technical replicates. Data were analyzed by using one-way analysis of variance with a Bonferroni posttest
adjustment. (C) The presence of SAM in the medium (0.5 mM) prevented the decrease in ATP levels observed in
the H_OFF strain upon Dox addition. In fact, ATP levels were increased compared to the minus Dox condition.
Graphs depict the means and SD of two biological and four technical replicates. (D) Expression of MetH-GFP in the
H_OFF background showed that the protein localized in both the cytoplasm and the nucleus. Singular channels are
shown in gray scale. In the composite image, magenta indicates DAPI and green indicates GFP. Scale bar, 10 m.
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it is unlikely that the fungus could find sufficient SAM during infection to compensate
for the defect in ATP caused by targeting methionine synthase.
S-Adenosylmethionine plays a fundamental role as methyl donor for the majority of
cellular methylation reactions, including methylation of DNA. Given the observed
importance of SAM in the absence of MetH activity and considering that in P. pastoris
and C. albicans methionine synthase was reported to localize in the nucleus, as well as
in the cytoplasm (34), we speculated that nuclear localization might be important for
MetH cellular function. To test this hypothesis, we constructed strains expressing
different versions of C terminus GFP-tagged MetH from the pJA49 plasmid (see Fig. S1F)
in the H_OFF background. These were a wild-type MetH, a MetHD616A (control of no
growth [Fig. 1C; see also Fig. S4A in the supplemental material]) and a MetHR749A
(metHg2439CGGA) version of the protein, which according to the results published for P.
pastoris should not localize in the nucleus (34). The strain expressing wild-type MetH
grew normally in restrictive conditions (see Fig. S4A), proving that the tagged MetH-
GFP protein was active. Importantly, this result also demonstrated that genetic down-
regulation of metH is the only reason for the lack of growth of the H_OFF strain in the
presence of Dox. We confirmed that A. fumigatus MetH localizes in both the nucleus
and the cytoplasm (Fig. 4D; see also Fig. S4B in the supplemental material). In contrast
to what was described in P. pastoris, the MetHR749A protein seems to be active, since it
could trigger growth of H_OFF in restrictive conditions (see Fig. S4A) and still localized
into the nucleus (see Fig. S4B). Therefore, the possibility that MetH localization in the
nucleus is important needs further exploration.
Repression of methionine synthase causes growth inhibition in growing my-
celia. The major advantage of the tetOFF system is that it can be used to simulate a
drug treatment before a specific chemical is developed. The addition of Dox to a
growing mycelium downregulates the gene of interest (see Fig. S1A), mimicking the
effect of blocking its product by the action of a drug. The validity of the Tet systems has
recently been questioned, since it has been reported that Dox can impair mitochondrial
function in various eukaryotic models (70). Nevertheless, existing evidence suggests
that low concentrations of Dox (50 g/ml) have little effect on fungal cells. For
instance, in contrast to reports of Dox affecting proliferation of human cells at low
concentrations (70, 71), we and others have not detected negative effects of low
concentrations of Dox or of tetracycline on fungal proliferation (Fig. 5A), phenotype
(macroscopic or microscopic; Fig. 5B), or virulence (17, 72–78). In addition, it was
reported that 40 g/ml of Dox does not affect the transcriptional profile of S. cerevisiae
(79), which contrasts with the broad effect caused by only 1 g/ml Dox on global
transcription in human cells (70). Moreover, a study that investigated the role of various
mitochondrial proteins for its function in C. albicans did not observe any negative effect
of 20 g/ml Dox on fungal growth nor on mitochondrial morphology and function (80).
To test the effect of Dox on A. fumigatus, we grew the wild-type strain overnight in
various concentrations of drug and imaged mitochondria using the Rhodamine 123 dye
(see Fig. S5 in the supplemental material). It was previously described that inhibition of
translation in mitochondria (mechanism of Dox toxicity) promotes mitochondrial fis-
sion, which can be detected as a more fragmented, punctuate, mitochondrial appear-
ance compared to the healthy tubular morphology (70, 80). This fragmented pheno-
type started to appear, although there was variation among hyphae, when the fungus
was incubated in 100 g/ml Dox and became obvious when it was incubated in
1,000 g/ml Dox (see Fig. S5). In contrast, in low concentrations of Dox (1 and 10 g/ml
Dox) the mitochondria showed a healthy tubular morphology, indistinguishable from
that of no Dox (see Fig. S5). Therefore, low concentrations of Dox do not affect
mitochondria morphology and thus likely do not impair their function. In fact, we have
also observed that addition of 5 g/ml Dox to wild-type mycelium did not affect the
ATP content (Fig. 3B), further supporting the conclusion that mitochondrial function is
not impaired. Therefore, even if higher concentrations of Dox have a negative effect on
fungal cells (74, 78), its impact at low concentrations on fungal cells seems to be
minimal. Consequently, we argue that as long as the concentration of Dox used is
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FIG 5 Repression of metH transcription causes inhibition of growth in vitro. (A) Addition of 1 g/ml Dox to mycelia grown for 12 and 16
h grown strongly reduced fungal biomass, as measured 24 h later. This was more pronounced in media without methionine. The effect
was lost when Dox was added 24 h after inoculation. For comparison, fungal biomass of mycelia harvested at the time of Dox addition
(12, 16, and 24 h postinoculation) is shown. Three independent experiments were performed, using three technical replicates for each.
(B) Microscopic images of 8-h-germinated spores treated with 10 g/ml Dox. Images were taken 16 h after Dox addition (wide-field
microscopy) and again 24 h later (stereomicroscopy). Dox addition halts growth of H_OFF strain in a sustained manner. (C) Time-lapse
microscopy of H_OFF growth upon Dox addition. Dox was added to 8-h-grown conidia, which caused growth inhibition that was obvious
after 4 h. Growth was virtually halted for as long as Dox was present. (D) At 6 h after Dox withdrawal, H_OFF growth resumed, showing
that the effect was fungistatic.
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50 g/ml, the tetOFF system can be utilized to investigate the consequences of
downregulating gene expression in fungal research.
To investigate the effect of downregulating metH for mycelial growth, we added
Dox to 12, 16, or 24 h grown submerged mycelia and left it incubating for an additional
24 h. Addition of Dox to 12 or 16 h grown mycelia severely impaired growth of the
H_OFF strain but not the wild type, as observed by biomass (Fig. 5A) and optical density
(OD; see Fig. S6A) measurements. This effect was lost when Dox was added to
24-h-grown mycelia due to the incapacity of Dox to reach and downregulate expres-
sion in all cells within the dense mass of an overgrown mycelium. Interestingly, Dox
addition to methionine free media stopped H_OFF growth immediately, which can be
observed by comparing fungal biomass at the time of Dox addition to the measure-
ment 24 h after Dox addition. In contrast, the fungus inoculated in methionine
containing media grew a little further after Dox addition (Fig. 5A). To understand this
difference, we added Dox to either resting or 8 h germinated conidia and imaged them
16 and 40 h after drug addition (Fig. 5B; see also Fig. S6B in the supplemental material).
In agreement with the previous result, we observed that Dox addition in methionine
free medium inhibited growth immediately: resting conidia did not germinate and
germinated conidia did not elongate the germ tube. In contrast, after the addition of
Dox in methionine-containing medium, most of the resting conidia were still able to
germinate and some germlings could elongate the germinated tubes to form short
hyphae. This suggests that the drop in ATP levels takes ca. 3 to 4 h before having an
effect on growth. Importantly, once growth was inhibited, the effect was sustained for
a long period, since we could not detect further growth up to 40 h postinoculation. To
corroborate these observations and further determine whether the effect of growth is
fungistatic or fungicidal in the long term, we performed a time-lapse analysis of the
effects of adding Dox to 8 h swollen conidia and its subsequent withdrawal after 16 h
of incubation in a medium containing methionine (Fig. 5C; see also Video S1 in the
supplemental material). We observed that growth was inhibited 4 h after Dox
addition and almost completely halted after 6 h, which was sustained as long as the
drug was present. Upon withdrawal of Dox, growth resumes within 6 h (Fig. 5D; see also
Video S1), showing that the effect of blocking MetH is fungistatic, at least with the
genetic TetOFF model of metH repression. As expected, Dox had no effect on wild-type
growth (see Video S2).
Targeting MetH in established infections interferes with the progression of
disease. We previously used the TetON system to investigate the relevance of MetH in
A. fumigatus virulence (17). In this model, metH gene expression was active when mice
were fed with Dox, which resulted in full virulence of the metH_tetON strain (demon-
strating that the concentration of Dox reached in murine tissues does not impact fungal
virulence). In the absence of Dox the gene was not expressed, which completely
abrogated virulence. This proved that the murine lung does not readily provide the
conditions to overcome the conditional essentiality of metH, and thus this gene is
required to establish infection. However, antifungal drugs are normally administered to
treat patients who already have an established infection. Therefore, it is possible that
the conditional essentiality of the gene could be overcome when the fungus is actively
growing in the tissue, since the fungal metabolic requirements and the environmental
conditions are different (53, 54). Consequently, in order to achieve a rigorous target
validation, it is crucial to assess the efficiency of new target candidates in established
infections. The first conditional promoter system used for A. fumigatus in vivo was the
(p)niiA (52). This system represses genetic expression of the gene of interest in the
presence of ammonium, which is contained in murine serum. Accordingly, in this
seminal study several genes essential in vitro were confirmed or refuted to be essential
to initiate infection in a model of systemic (blood) infection. Currently, two more
systems are in use to assess the relevance of fungal essential genes for pulmonary
infection: TetON and (p)xylP. These systems can be used to either impede or permit
fungal gene expression in murine lungs; but in both models, this control can only be
exerted from the beginning of infection, since sufficient levels of the inducing molecule
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(doxycycline or xylose) must be present to activate gene expression in the control
condition. Consequently, these models have been used to investigate the relevance of
genes required to grow in vitro to initiate pulmonary infection (17, 76, 81). However, we
believe these models are not adequate to determine the importance of the genes in
established aspergillosis infections in vivo. This is because in this models complete
elimination of the inducing metabolite (Dox or xylose), which is required to prevent
expression of the gene of interest, would be gradual and take several hours after its
withdrawal, which impedes a precise control of the time of intervention. Therefore, we
aimed to optimize the use of the TetOFF system for this purpose because it can be used
to downregulate gene expression in growing mycelia at a precise time. As a control for
the model, we constructed a cyp51A_tetOFFcyp51B (51A_OFF) strain. We reasoned that
the target of the azoles, first-line treatment drugs for Aspergillus diseases, should be the
gold standard to compare any target against. This strain showed a similar behavior as
H_OFF in vitro: as little as 0.05 g/ml Dox prevented colony development on an agar
plate (see Fig. S7A), and the addition of Dox to conidia or germlings blocked growth
(see Fig. S7B).
We first assayed the use of the TetOFF system in the Galleria mellonella alternative
mini-host model of infection. Preliminary experiments revealed that the balance be-
tween reaching sufficient levels of Dox to exert an effect and maintaining toxic effects
of overdose low was very delicate. We finally optimized a regimen consisting of five
injections of 50 mg/kg Dox (see Fig. S7C) that caused little mortality in the control
group (25% in the Dox control versus 12% in the PBS treatment control P  0.22) but
still showed an effect of treatment (Fig. 6A). We then infected Galleria larvae with
5  102 conidia of 51A_OFF or H_OFF strains and applied the Dox regimen or PBS
vehicle starting at the same time of infection (0 h) or 6 h after infection (see Fig. S7C).
For both strains, administration of Dox from the beginning of infection triggered a
significant improvement in survival compared with the nontreated conditions (50%
versus 17.2% for 51A_OFF [P  0.0036] and 41.45% versus 6.67% for H_OFF [P  0.022])
(Fig. 6A). The fact that administration of Dox at the time of infection did not improve
survival to close to 100%, was not surprising, since it is important to note that Dox does
not completely prevent gene expression (see Fig. S1A), so a moderate effect on survival
was expectable. Furthermore, rapid metabolization of the drug in the larvae hemocoel
or microenvironment variations in its concentration may also account for a discrete
effect of treatment. Despite this limitation of the model, we observed that administra-
tion of Dox 6 h after infection also triggered a significant improvement in survival for
both strains (42.8% versus 17.2% for 51A_OFF [P  0.0007] and 32.26% versus 6.67% for
H_OFF [P  0.0324]) (Fig. 6A). Therefore, downregulation of methionine synthase
genetic expression in established infections conferred a significant benefit in survival
which was comparable to that observed with the target of the azoles.
The positive results obtained using the Galleria infection model prompted us to
assay the TetOFF system in a leukopenic murine model of pulmonary aspergillosis.
To ensure that Dox levels in mouse lungs reach and maintain sufficient concentrations
to downregulate gene expression (according to our results in vitro) we performed a
pilot Dox dosage experiment in immunosuppressed noninfected mice (see Fig. S7D).
We extracted the lungs of Dox-treated mice at different time points, homogenated
them and measured Dox concentration using a bioassay based on inhibition of
Escherichia coli BL21(DE3) growth. We could detect promising levels of Dox in all mice
(concentrations ranging from 2.2 to 0.9 g/ml; see Fig. S7D), which according to our
results in vitro should be sufficient to downregulate gene expression from the TetOFF
system. We therefore infected leukopenic mice with 105 spores of the 51A_OFF or the
H_OFF strains and administered PBS vehicle or our Dox regimen, starting 16 h after
infection (Fig. S7D). The use of an uninfected, Dox-treated control group uncovered
that the intense Dox regimen used was harmful for the mice. These uninfected mice
lost weight at a similar rate as the infected groups and looked ill from the third or fourth
day of treatment. This is not surprising as Dox can impair mitochondrial function in
mice (70) and has iron chelating properties (82). As a consequence, there was no
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beneficial effect of Dox treatment on survival (not shown). The fact that Dox treatment
did also not show any benefit in survival for our control strain 51A_OFF, which should
mimic treatment with azoles (primary therapy for invasive aspergillosis), indicates that
the TetOFF system is not ideal to mimic a drug treatment in established infections.
Nevertheless, we further attempted to determine the efficiency of targeting MetH in
established infections by measuring fungal burdens in lungs of treated and untreated
mice. We observed that two and a half days of Dox treatment (when the mice have not
developed visible toxic effects yet) did result in a significant reduction of fungal
burdens 3 days after infection for both 51A_OFF (P  0.0279) and H_OFF (P  0.0019)
(Fig. 6B). Therefore, we could observe a beneficial effect of interfering with methionine
synthase genetic expression in an established pulmonary infection, which was compa-
rable to that of interfering with the expression of cyp51A, the target of azoles. This
constitutes a very rigorous validation of MetH as a promising antifungal target.
A recent study also aimed to use another TetOFF system to validate a drug target
in established aspergillosis infections (83). These authors administered Dox exclusively
through oral gavage, accounting for lower dosage of drug. Consequently, even if no
FIG 6 Downregulation of metH in vivo in established infections shows a beneficial effect comparable to
the target of azoles. (A) Administration of a Dox regimen (see also Fig. S7C) to Galleria mellonella infected
with either the H_OFF strain or the 51A_OFF control strain showed a beneficial effect in survival. For both
strains, starting regimen at the time of infection triggered a significant improvement in survival (50%
versus 17.2% for 51A_OFF [P  0.0036] and 41.45% versus 6.67% for H_OFF [P  0.022]). A Dox regimen
6 h after infection also triggered a significant improvement in survival for both strains (42.8% versus
17.2% for 51A_OFF [P  0.0007] and 32.26% versus 6.67% for H_OFF [P  0.0324]). The curves show the
pooled data from three independent experiments. Curves were compared using a log-rank test. (B)
Leukopenic mice were infected with 51A_OFF or H_OFF using a Dox regimen (Fig. S7D) administered 16
h after infection. Upon Dox treatment, the fungal burden in the lungs was significantly reduced for both
strains (P  0.0279 for 51A_OFF and P  0.0019 for H_OFF). Two independent experiments were carried
out. Each point in the graphs represents one mouse (n  9). Burdens for each strain were compared
using a Mann-Whitney test.
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toxic effect for the mice was observed, they also did not detect any beneficial effect on
survival when the Dox treatment was initiated after infection. Therefore, the TetOFF
system is clearly not optimal and better models are needed. Yet, it is currently the only
model with which the efficiency of new targets can be tested in aspergillosis estab-
lished infections, and thus it is highly valuable that we have been able to optimize its
use in vivo. Our 51A_OFF control strain has been key to calibrating the model and allows
us to be confident that the beneficial effects observed, even if subtle, are significant.
Hence, we propose that using our model to gain information about the relevance of
prospective molecular targets in established infections would be a valuable addition for
a more comprehensive genetic validation of antifungal targets.
Structure-based virtual screening of MetH. Having shown in vivo that MetH is a
promising target, we decided to investigate its druggability by running a structure-
based virtual screening. The sequence of A. fumigatus MetH (AfMetH) contains two
predicted methionine synthase domains with a -barrel fold conserved in other fungal
and bacterial enzymes. The structure of the C. albicans orthologue (84) (CaMetH)
showed that the active site is located between the two domains where the methyl
tetrahydrofolate, the homocysteine substrate and the catalytic zinc ion bind in close
proximity. The homology model for AfMetH (Fig. 7A) overlaps very well with that of the
CaMetH thus providing a suitable molecular model for further analysis. In contrast, the
structure of the human methionine synthase (hMS) shows a very different overall
FIG 7 Virtual screening of fungal and human methionine synthases reveals different druggabilities of the
proteins. (A) The structures of the crystallized C. albicans and the predicted A. fumigatus methionine
synthases are highly similar. (B) In contrast, the structure of the human enzyme is very different, having
the 5-methyl-tetrahydrafolate and homocysteine binding sites separated. (C) Detail of the active site of
fungal methionine synthases, with the methionine, folate, and zinc displayed. (D) Tetrahydrofolate
binding site of the human protein. (E) Virtual screening on the A. fumigatus protein found four ligand
binding clusters in the structure, two of which (C1 and C2) match the binding position of the
5-methyl-tetrahydrafolate and the methionine. (F) In the human enzyme, two clusters were found, one
(C1) that overlaps with the tetrahydrofolate binding site and (another C2) in a nearby pocket.
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arrangement with the folate and homocysteine binding domains located in completely
different regions (Fig. 7B). Comparison of the tetrahydrofolate binding sites between
the fungal and the human structures also highlights significant structural differences
that affect the conformation adopted by the ligand. In the CaMetH structure the
5-methyl-tetrahydrofolate (C2F) adopts a bent conformation (20 Å long), and it is in
close proximity to the methionine product, whereas in the human structure the
tetrahydrofolate (THF) ligand binds in an elongated conformation extending up to 30 Å
from end to end (Fig. 7C and D).
Virtual screening (VS) was carried on the AfMetH and the hMS structures with the
Maybridge Ro3 fragment library to explore potential venues for drug development. The
results showed four ligand binding clusters in the AfMetH structure, two of which (C1
and C2) match the binding position of the 5-methyl-tetrahydrafolate and the methio-
nine from the CaMetH crystal structure (Fig. 7E). For the hMS, we found two main
clusters, C1 that overlaps with the tetrahydrofolate binding site and C2 in a nearby
pocket. Clearly, the distribution of the clusters defines a very different landscape
around the folate site between the human and the fungal enzymes. Furthermore, the
proximity of the C1 and C2 clusters, matching the folate and Met/homocysteine
binding sites in the Ca/Af proteins means that it may be possible to combine ligands
at both sites to generate double-site inhibitors with high specificity toward the fungal
enzymes. Antifolates are a class of drugs that antagonize folate, blocking the action of
folate dependent enzymes such as dihydrofolate reductase (DHFR), thymidylate syn-
thase or methionine synthase. Methotrexate is an antifolate commonly used to treat
cancer and autoimmune diseases. Interestingly, methotrexate has been shown to be a
weak inhibitor of the C. albicans methionine synthase (33) and to have some antifungal
activity against C. albicans (85) and Aspergillus spp. (86). Nevertheless, methotrexate is
not a good antifungal drug, as its activity is high against human enzymes (50%
inhibitory concentration [IC50] of 0.3 M for DHFR [87]) and low against fungal methi-
onine synthase (IC50 of 4 mM for C. albicans MetH [33]). Therefore, more potent and
specific inhibitors of fungal methionine synthases are needed to fully exploit the value
of this target for antifungal therapy, a task that seems possible and can be directed
from our analyses.
In summary, we have shown that methionine synthase blockage triggers not only
methionine auxotrophy but also a metabolic imbalance that results in a drop in cellular
energetics and growth arrest. In light of our results, we stress that conditional essen-
tiality is important to understand the underlying mechanisms of metabolic processes
and needs to be considered to achieve proper validation of novel antimicrobial targets.
Accordingly, we proved that targeting methionine synthase in established infections
has a beneficial effect similar to that observed for the target of azoles, the most
effective drugs for the treatment of aspergillosis. Finally, we showed that fungal
methionine synthases have distinct druggable pockets that can be exploited to design
specific inhibitors. In conclusion, we have demonstrated that fungal methionine syn-
thases are promising targets for the development of novel antifungals.
MATERIALS AND METHODS
Strains, media, and culture conditions. The Escherichia coli strain DH5 (88) was used for cloning
procedures. Plasmid-carrying E. coli strains were routinely grown at 37°C in Luria-Bertani (LB) liquid
medium (Oxoid) under selective conditions (100 g ml	1 ampicillin or 50 g ml	1 kanamycin); for
growth on plates, 1.5% agar was added to solidify the medium. All plasmids used in the course of this
study were generated using Seamless Cloning (Invitrogen) technology, as previously described (17, 89).
E. coli strain BL21(DE3) (90) was grown on Mueller-Hinton agar (Sigma) in bioassays to determine Dox
concentrations within homogenized murine lungs.
The wild-type clinical isolate Aspergillus fumigatus strain ATCC 46645 served as reference recipient. A.
fumigatus strain A1160 (ku80) (91) was also used to confirm metH essentiality. A. fumigatus mutants
were generated using a standard protoplasting protocol (92). A. fumigatus strains were generally cultured
in minimal medium (MM) (93) (1% glucose, 5 mM ammonium tartrate, 7 mM KCl, 11 mM KH2PO4,
0.25 mM MgSO4, 1 Hutner’s trace elements solution [pH 5.5], 1.5% agar) at 37°C. For selection in the
presence of resistance markers 50 g ml	1 of hygromycin B or 100 g ml	1 of pyrithiamine (InvivoGen)
were applied. In sulfur-free medium (MM–S), MgCl2 substituted for MgSO4 and a modified mixture of
trace elements lacking any sulfate salt was used. For all growth assays on solid media, the culture
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medium was inoculated with 10 l of a freshly prepared A. fumigatus spore suspension (105 conidia ml	1
in water supplemented with 0.9% NaCl and 0.02% Tween 80) and incubated at 37°C for 3 days.
Extraction and manipulation of nucleic acids. Standard protocols of recombinant DNA technology
were carried out (94). Phusion high-fidelity DNA polymerase (Thermo Fisher Scientific) was generally used
in polymerase chain reactions, and essential cloning steps were verified by sequencing. Fungal genomic
DNA was prepared according to the protocol of Kolar et al. (95), and Southern analyses were carried out
as described previously (96, 97), using the Amersham ECL direct labeling and detection system (GE
Healthcare). Fungal RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) and a Qiagen plant
RNA extraction kit. Retrotranscription was performed using SuperScript III first-strand synthesis (Thermo
Fisher Scientific). RT-PCR on both gDNA and cDNA was performed using the SYBR Green JumpStart
(Sigma) in a 7500 Fast Real Time PCR cycler from Applied Biosystems.
Microscopy. A total of 103 A. fumigatus resting or 8 h germinated conidia were inoculated in 200 l
of medium (with or without Dox) in 8-well imaging chambers (Ibidi) and incubated at 37°C. Microscopy
images were taken on a Nikon Eclipse TE2000-E, using a CFI Plan Apochromat Lambda 20/0.75
objective, and captured with a Hamamatsu Orca-ER CCD camera (Hamamatsu Photonics) and manipu-
lated using NIS-Elements 4.0 (Nikon). For extensively grown mycelia a stereomicroscope Leica MZFL-III
was used, with a Q-imaging Retinga 6000 camera, and manipulated using Metamorph v7760. Confocal
imaging was performed using a Leica TCS SP8 inverted confocal microscope equipped with a 40/0.85
objective. Nuclei were stained with DAPI (4=,6=-diamidino-2-phenylindole; Life Technologies, Ltd.) as
described previously (98). GFP was excited at 458 nm with an argon laser at 20% power. DAPI was excited
at 405 nm with an LED diode at 20%.
Metabolome analyses. A. fumigatus wild-type and metH_tetOFF strains were incubated in MM for 16
h before the 	Dox samples were taken (8 replicates of 11 ml each). Then, 5 g/ml Dox and 5 mM
methionine (to prevent metabolic adaptation due to met auxotrophy) were added as appropriate, and
the cultures incubated for 6 h; Dox samples were then taken (8  11 ml). The samples were immedi-
ately quenched with 2 volumes of 60% methanol at 	48°C. After centrifugation at 4,800  g for 10 min
at 	8°C, metabolites were extracted in 1 ml 80% methanol at 	48°C by three cycles of N2 liquid
snap-freezing, thawing, and vortexing. Supernatant was cleared by centrifugation at 	9°C, 14,500  g for
5 min. Quality control (QC) samples were prepared by combining 100 l from each sample. Samples were
aliquoted (300 l), followed by the addition of 100 l of the internal standard solution (0.2 mg/ml
succinic-d4 acid and 0.2 mg/ml glycine-d5) and vortex mixing for 15 s. All samples were lyophilized by
speed vacuum concentration at room temperature overnight (HETO VR MAXI vacuum centrifuge
attached to a Thermo Svart RVT 4104 refrigerated vapor trap; Thermo Life Sciences, Basingstoke, UK). A
two-step derivatization protocol of methoxyamination followed by trimethylsilylation was used (99).
GC-MS analysis was conducted on a 7890B GC coupled to a 5975 series MSD quadrupole mass
spectrometer and equipped with a 7693 autosampler (Agilent Technologies, UK). The sample (1 l) was
injected onto a VF5-MS column (30 m  0.25 mm  0.25 m; Agilent Technologies) with an inlet
temperature of 280°C and a split ratio of 20:1. Helium was used as the carrier gas with a flow rate of
1 ml/min. The chromatography was programmed to begin at 70°C with a hold time of 4 min, followed
by an increase to 300°C at a rate of 14°C/min and a final hold time of 4 min before returning to 70°C. The
total run time for the analysis was 24.43 min. The MS was equipped with an electron impact ion source
using 70 eV ionization and a fixed emission of 35 A. The mass spectrum was collected for the range 50
to 550 m/z with a scan speed of 3,125 (n  1). Samples were analyzed in a randomized order with the
injection of a pooled biological quality control sample after every sixth sample injection.
For data analysis, the GC-MS raw files were converted to mzXML and subsequently imported into R.
The R package “erah” was used to deconvolve the GC-MS files. Chromatographic peaks and mass spectra
were cross-referenced with the Golm library for putative identification purposes, and followed the
metabolomics standards initiative (MSI) guidelines for metabolite identification (100). The peak intensi-
ties were normalized according to the IS (succinic-d4 acid) before being log10 scaled for further statistical
analysis. All preprocessed data were investigated by using PCA (101).
The raw data of this metabolome analysis has been deposited in the MetaboLights database (102),
under the reference MTBLS1636 (www.ebi.ac.uk/metabolights/MTBLS1636).
ATP quantitation. A. fumigatus was grown as in the metabolome analysis. However, where the effect
of SAM was investigated spores were inoculated into MM–N  1 mg/ml aac, and 0.5 mM SAM was also
added at the time of Dox addition. ATP levels were determined using the BacTiter-Glo assay (Promega)
according to the manufacturer’s instructions and a TriStar LB 941 microplate reader (Berthold).
Isolation and detection of SAM. A. fumigatus was grown exactly under the same conditions as
described for the metabolome analysis. Harvested mycelia were snap-frozen in liquid N2 and stored at
	70°C before SAM isolation. SAM extraction was carried out as described by Owens et al. (103). Briefly,
frozen mycelia were ground in liquid N2, and 0.1 M HCl (250 l) was added to ground mycelia (100 mg).
Samples were stored on ice for 1 h, with sample vortexing at regular intervals. Samples were centrifuged
at 13,000  g for 10 min (4°C) to remove cell debris, and supernatants were collected. The concentration
of protein in supernatants was determined using a Bio-Rad Bradford protein assay relative to a bovine
serum albumin (BSA) standard curve. Clarified supernatants were adjusted to 15% (wt/vol) trichloroacetic
acid to remove protein. After 20 min of incubation on ice, centrifugation was repeated and clarified
supernatants were diluted with 0.1% (vol/vol) formic acid. Samples were injected onto a Hypersil Gold
aQ C18 column with polar endcapping on a Dionex UltiMate 3000 nanoRSLC with a Thermo Q-Exactive
mass spectrometer. Samples were loaded in 100% solvent A (0.1% [vol/vol] formic acid in water),
followed by a gradient to 20% solvent B (0.1% [vol/vol] formic acid in acetonitrile) over 4 min. Resolution
set to 70,000 for MS, with MS/MS scans collected using a Top3 method. SAM standard (Sigma) was used
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to determine retention time and to confirm MS/MS fragmentation pattern for identification. Extracted ion
chromatograms were generated at m/z 399 to 400, and the peak area of SAM was measured. Measure-
ments were taken from three biological and two technical replicates per sample, normalized to the
protein concentration in the extracts from each replicate. SAM levels are expressed as a percentage
relative to the parental strain in the absence of Dox.
Nucleus isolation and Western blotting. Protoplasts were generated as in A. fumigatus transfor-
mations, and nuclei were isolated by sucrose gradient fractionation as previously described by Sperling
and Grunstein (104). Nuclear localization of GFP-tagged target proteins was confirmed by Western
blotting. Aliquots of nuclei were boiled for 5 min in loading buffer (0.2 M Tris-HCl, 0.4 M dithiothreitol,
8% SDS, trace bromophenol blue) and separated on a 12% (wt/vol) SDS-PAGE gel. The proteins were
transferred to a polyvinylidene difluoride membrane using the Trans-Blot Turbo transfer system (Bio-
Rad). Detection of GFP was carried out with a rabbit polyclonal anti-GFP antiserum (Bio-Rad) and
anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology). SuperSignal West Pico PLUS Chemilu-
minescent Substrate (Thermo Scientific) and the ChemiDoc XRS Imaging System (Bio-Rad) were used
to visualize immunoreactive bands. Ponceau S staining was performed to normalize the Western blotting
signal to the protein loading.
Mitochondrion imaging. Approximately 200 A. fumigatus spores were seeded onto Ibidi 8-well
slides in minimal medium containing 0, 1, 10, 100, and 1,000 g/ml Dox and incubated at 37°C for 16 h.
The culture medium was then replaced with minimal medium containing the same Dox concentrations
plus 10 M rhodamine-123 dye and further incubated for 1 to 2 h at 37°C prior to live-cell confocal
imaging. High-resolution confocal fluorescence imaging was performed at 37°C on a Leica SP8x using a
63/1.3 NA oil immersion lens, whereby the rhodamine-123 fluorescence was excited with a white light
laser (5%) tuned to 508 nm, and the emission was collected on HyD detectors set to 513 to 600 nm.
Representative single-plane images of each condition were background subtracted (rolling ball 20 pixel
radius) in Fiji (105) and montaged using FigureJ (106).
Biomass measurement. Conidia were inoculated into MM–S, supplemented with either methionine
or sulfate, and incubated at 37°C and 180 rpm for 12, 16, or 24 h. After this initial incubation, 3-ml
samples were taken in triplicate from the cultures, filtered through tared Miracloth, and dried at 60°C for
16 h, and their biomass was measured. In treated conditions Dox was added to a final concentration of
1 g/ml, and the culture was allowed to grow for a further 24 h at 37°C and 180 rpm. Then, 5-ml samples
were taken in triplicate, and their biomass was measured as above.
Galleria mellonella infections. Sixth-stage instar larval G. mellonella moths (15 to 25 mm in length)
were ordered from the Live Foods Company (Sheffield, United Kingdom). Infections were performed
according to Kavanagh and Fallon (107). Randomly selected groups of 15 larvae were injected in the last
left proleg with 10 l of a suspension of 5  104 conidia/ml in PBS, using Braun Omnican 50-U 100 0.5-ml
insulin syringes with integrated needles. Dox was administered according to the treatment shown in
Fig. S7C, alternating injections in the last right and left prolegs. In each experiment, an untouched and
a saline injected control were included to verify that mortality was not due to the health status of the
larvae or the injection method. Three independent experiments were carried out. The presented survival
curves display the pooled data, which was analyzed with a log-rank test.
Ethics statement. All mouse experiments were performed under United Kingdom Home Office
project license PDF8402B7 and approved by the University of Manchester Ethics Committee and by the
Biological Services Facility at the Faculty of Biology, Medicine and Health, University of Manchester.
Leukopenic murine model of invasive pulmonary aspergillosis and calculation of fungal
burden. Outbred CD1 male mice (22 to 26 g) were purchased from Charles Rivers and left to rest for at
least 1 week before the experiment. Mice were allowed access ad libitum to water and food throughout
the experiment. Mice were immunosuppressed with 150 mg/kg of cyclophosphamide on days 	3 and
	1 and with 250 mg/kg cortisone acetate on day 	1. On day 0 mice were anesthetized with isoflurane
and intranasally infected with a dose of 105 conidia (40 l of a freshly harvested spore solution of
2.5  106 conidia/ml). Dox was administered according to the treatment shown in Fig. S7D. Dox
containing food was purchased from Envingo (Safe-Diet U8200 version 0115 A03 0.625 g/kg Doxycycline
Hyclate pellets). At the selected time point (72 h after infection for fungal burden), mice were sacrificed
by a lethal injection of pentobarbital, and the lungs were harvested and immediately snap frozen.
Frozen lungs were lyophilized for 48 h in a CoolSafe ScanVac freeze drier connected to a VacuuBrand
pump and subsequently ground in the presence of liquid nitrogen. DNA was isolated from the powder
using the DNeasy blood and tissue kit (Qiagen). DNA concentration and quality were measured using a
NanoDrop 2000 (Thermo Fisher Scientific). To detect the fungal burden, 500-ng portions of DNA
extracted from each infected lung were subjected to qPCR. Forward (5=-ACTTCCGCAATGGACGTTAC-3=)
and reverse (5=-GGATGTTGTTGGGAATCCAC-3’) primers were used to amplify the A. fumigatus -tubulin
gene (AFUA_7G00250). The primers designed to amplify the murine actin locus (NM_007393) were as
follows: forward (5=-CGAGCACAGCTTCTTTGCAG-3=) and reverse (5=-CCCATGGTGTCCGTTCTGA-3=). Stan-
dard curves were calculated using different concentrations of fungal and murine gDNA pure template.
Negative controls containing no template DNA were subjected to the same procedure to exclude or
detect any possible contamination. Three technical replicates were prepared for each lung sample. qPCRs
were performed using the 7500 Fast Real-Time PCR system (Thermo Fisher Scientific) with the following
thermal cycling parameters: 94°C for 2 min and 40 cycles of 94°C for 15 s and 59°C for 1 min. The fungal
burden was calculated by normalizing the number of fungal genome equivalents (i.e., the number of
copies of the tubulin gene) to the murine genome equivalents in the sample (i.e., the number of copies
of the actin gene) (108). Two independent experiments were carried out (n  9, five mice in the first
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experiment and four mice in the second experiment). The burdens for each strain were compared by
using a Mann-Whitney test.
Molecular homology models and virtual screening. The full-length sequence for AFUA_4G07360,
the cobalamin-independent methionine synthase MetH from A. fumigatus (AfMetH) was obtained from
FungiDB (https://fungidb.org/fungidb) (109). This sequence, together with the structure of the C. albicans
orthologue (CaMetH) (PDB ID 4L65; doi:10.1016/j.jmb.2014.02.006), was used to create the molecular
homology model in Modeller (v9.23) (110) with the basic option mode. The AfMetH model was then used
for virtual screening with the semiautomated pipeline VSpipe (111). For comparison, we also performed
virtual screening with the structure of the human methionine synthase containing the folate and
homocysteine binding domains (PDB ID 4CCZ). Docking was done using the Maybridge Ro3 1000
fragment library with AutoDock Vina (112). The results were inspected graphically by using PyMOL
(v1.8.0.3 Enhanced for Mac OS X; Schrödinger). All images were produced by using PyMOL.
Data availability. The raw data that support the findings of this study are available upon reasonable
request to the authors. The raw data from the metabolome analysis have been deposited in the
MetaboLights database (102) under the reference MTBLS1636 (www.ebi.ac.uk/metabolights/
MTBLS1636).
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